November 24, 2014 12:33 AM ET

Pharmaceuticals

Company Overview of Aciex Therapeutics, Inc.

Company Overview

Aciex Therapeutics, Inc. develops ophthalmic pharmaceutical products to treat ocular diseases. It offers products to treat dry eye, aesthetic ocular conditions, infectious diseases, allergic conjunctivitis, inflammation, ocular pain, glaucoma, and retinal degenerative diseases. Aciex Therapeutics, Inc. was formerly known as Aciex, Inc. and changed its name to Aciex Therapeutics, Inc. in October 2007. Aciex Therapeutics, Inc. was founded in 2007 and is based in Westborough, Massachusetts. As of October 27, 2014, Aciex Therapeutics, Inc. operates as a subsidiary of Nicox SA.

82 Flanders Road

Suite 102

Westborough, MA 01581-1069

United States

Founded in 2007

Phone:

508-439-4946

Fax:

508-638-6430

Key Executives for Aciex Therapeutics, Inc.

Executive Chairman
Age: 63
Scientific Advisor and Director
Scientific Advisor
Scientific Advisor
Compensation as of Fiscal Year 2014.

Aciex Therapeutics, Inc. Key Developments

Aciex Therapeutics Inc., Nicox SA - M&A Call

Nicox to acquire Aciex Therapeutics, Inc

Aciex Therapeutics Inc., Nicox SA - M&A Call

To discuss the acquisition of Aciex Therapeutics, Inc

Aciex Therapeutics Inc. Enters into Collaborative Research Agreement with Portola Pharmaceuticals, Inc. to Develop Dual Spleen Tyrosine Kinase/Janus Kinase Inhibitors for Ophthalmic Indications

Aciex Therapeutics Inc. announced that it has entered into a collaborative research agreement with Portola Pharmaceuticals, Inc. (Portola) that provides Aciex with exclusive rights to develop Portola's small molecule dual Spleen Tyrosine Kinase (Syk)/Janus Kinase (JAK) inhibitors for ophthalmic indications. The Portola library includes both compounds with extensive preclinical systemic data packages as well as earlier stage research compounds. The two companies will target development of drugs to treat topical ophthalmic diseases, including ocular allergy, dry eye and other inflammatory eye conditions, for which there is a strong scientific rationale for Syk and JAK inhibition. Under the terms of the agreement, Aciex will obtain access to Portola's small molecule dual Syk/JAK inhibitors and will lead clinical development activities for ophthalmic indications. Both companies will fund and participate in development activities related to the programs. Portola retains the right to develop these compounds for non-ophthalmic indications.

Similar Private Companies By Industry

Company Name Region
Channel Therapeutics Inc. United States
Russ Pharmaceuticals United States
Theregen, Inc. United States
Diabetica Research Solutions, Incorporated United States
MicroSource Discovery Systems, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
July 2, 2014
--
Private Placement
April 17, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Aciex Therapeutics, Inc., please visit www.aciexrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.